{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:34:59Z","timestamp":1789079699077,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T00:00:00Z","timestamp":1251072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p><jats:bold>Objectives. <\/jats:bold> To evaluate the incidence of infectious complications after receiving alemtuzumab as part of a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in Korean patients.<\/jats:p><jats:p><jats:bold>Methods. <\/jats:bold> From November 2004 to January 2006, 12 patients who received alemtuzumab\u2010based conditioning regimens for allogeneic HSCT were evaluated retrospectively until death or until the end of the follow\u2010up in July 2007; they were compared with 18 patients who received rabbit anti\u2010thymocyte globulin (ATG)\u2010containing conditioning regimens from January 2002 to January 2006.<\/jats:p><jats:p><jats:bold>Results. <\/jats:bold> Post\u2010engraftment infections occurred more frequently in the alemtuzumab recipients than in the ATG recipients; the mean number of infections, excluding cytomegalovirus (CMV) infections, per patient during the follow\u2010up period was 2.6\u00b11.4 vs. 1.0\u00b10.8 (<jats:italic>P<\/jats:italic>=0.003), respectively. Although there was no statistical difference in the cumulative incidence of CMV \u2003infection between the 2 groups (91.7% vs. 55.6%, <jats:italic>P<\/jats:italic>=0.381), the alemtuzumab recipients had a higher incidence of CMV\u2003 diseases (41.6% vs. 0%, <jats:italic>P<\/jats:italic>=0.0006) and a higher recurrence rate of CMV infection (90.0% vs. 27.3%, <jats:italic>P<\/jats:italic>=0.008) than did the ATG recipients, irrespective of the dose of alemtuzumab. Hemorrhagic cystitis (HC) (66.7% vs. 16.7%, <jats:italic>P<\/jats:italic>=0.009) and BK virus\u2010associated HC (41.7% vs. 5.6%, <jats:italic>P<\/jats:italic>=0.026) developed more frequently in the alemtuzumab recipients. The all\u2010cause mortality rate was not significantly different between the alemtuzumab and the ATG recipients (75% vs. 55.6%, <jats:italic>P<\/jats:italic>=0.28).<\/jats:p><jats:p><jats:bold>Conclusion. <\/jats:bold> Alemtuzumab recipients had a high incidence of CMV disease as well as BK virus\u2010associated HC compared with the ATG recipients. The dose of alemtuzumab should be tailored to patients' risk; in addition, the implementation of the appropriate prophylaxis for CMV and early detection strategies for BK virus are recommended.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2009.00414.x","type":"journal-article","created":{"date-parts":[[2009,8,25]],"date-time":"2009-08-25T01:48:01Z","timestamp":1251164881000},"page":"413-423","source":"Crossref","is-referenced-by-count":42,"title":["Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti\u2010thymocyte globulin"],"prefix":"10.1111","volume":"11","author":[{"given":"S.H.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010M.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.\u2010G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010H.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010H.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.\u2010J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010G.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.\u2010S.","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.\u2010S.","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.\u2010S.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.\u2010C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301206"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1767"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381405"},{"issue":"3","key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin S","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05632.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702477"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/146532401317070899"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704975"},{"issue":"4","key":"e_1_2_5_10_2","first-page":"1125","article-title":"Respiratory virus infections in transplant recipients after reduced\u2010intensity conditioning with Campath\u20101H","volume":"119","author":"Chakrabarti S","year":"2002","journal-title":"high incidence but low mortality"},{"issue":"12","key":"e_1_2_5_11_2","first-page":"4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation","volume":"99","author":"Chakrabarti S","year":"2002","journal-title":"potential role of Campath-1H in delaying immune reconstitution"},{"issue":"5","key":"e_1_2_5_12_2","first-page":"1619","article-title":"Adenovirus infections following allogeneic stem cell transplantation","volume":"100","author":"Chakrabarti S","year":"2002","journal-title":"incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V102.3.839"},{"issue":"1","key":"e_1_2_5_14_2","first-page":"69","article-title":"Risk\u2010adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation","volume":"81","author":"Choi SM","year":"2005","journal-title":"a single-center experience in Korea"},{"issue":"8","key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman P","year":"2002","journal-title":"Clin Infect Dis"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90380-0"},{"issue":"12","key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw B","year":"2008","journal-title":"Clin Infect Dis"},{"key":"e_1_2_5_19_2","first-page":"570","article-title":"Association of polyomaviruria with hemorrhagic cystitis in recipients with bone marrow transplants","volume":"20","author":"Park MJ","year":"2000","journal-title":"Korean J Clin Pathol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705121"},{"issue":"2","key":"e_1_2_5_21_2","first-page":"197","article-title":"Influence of cytomegalovirus (CMV) sero\u2010positivity on CMV infection, lymphocyte recovery and non\u2010CMV infections following T\u2010cell\u2010depleted allogeneic stem cell transplantation","volume":"33","author":"Chakrabarti S","year":"2004","journal-title":"a comparison between two T-cell depletion regimens"},{"issue":"3","key":"e_1_2_5_22_2","first-page":"273","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)\u2010seronegative recipients of stem cell transplants from seropositive donors","volume":"185","author":"Nichols WG","year":"2002","journal-title":"evidence for indirect effects of primary CMV infection"},{"key":"e_1_2_5_23_2","first-page":"277","volume-title":"Transplant Infections","author":"Boeckh MJ","year":"2003"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21215"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07184.x"},{"key":"e_1_2_5_26_2","first-page":"87","article-title":"Seroepidemiology of human cytomegalovirus in healthy adults measured by means of the anticomplement immunofluorescence technique","volume":"24","author":"Kim YK","year":"1992","journal-title":"Korean J Infect Dis"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705249"},{"issue":"6","key":"e_1_2_5_28_2","first-page":"2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease","volume":"90","author":"Salzberger B","year":"1997","journal-title":"risk factors and outcome"},{"issue":"12","key":"e_1_2_5_29_2","first-page":"1129","article-title":"Long\u2010term follow\u2010up of myeloablative allogeneic stem cell transplantation using Campath \u201cin the bag\u201d as T\u2010cell depletion","volume":"37","author":"Barge RM","year":"2006","journal-title":"the Leiden experience"},{"issue":"5","key":"e_1_2_5_30_2","first-page":"503","article-title":"Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation","volume":"37","author":"Juliusson G","year":"2006","journal-title":"influence of Campath dose on lymphoid recovery, mixed chimerism and survival"},{"issue":"11","key":"e_1_2_5_31_2","first-page":"929","article-title":"Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation","volume":"36","author":"Leung AY","year":"2005","journal-title":"a changing paradigm"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/511863"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705886"},{"issue":"3","key":"e_1_2_5_34_2","first-page":"1130","article-title":"BK DNA viral load in plasma","volume":"106","author":"Erard V","year":"2005","journal-title":"evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients"},{"issue":"12","key":"e_1_2_5_35_2","first-page":"1861","article-title":"BK virus infection in hematopoietic stem cell transplant recipients","volume":"39","author":"Erard V","year":"2004","journal-title":"frequency, risk factors, and association with postengraftment hemorrhagic cystitis"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.02.011"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.01.076"},{"issue":"1","key":"e_1_2_5_38_2","first-page":"404","article-title":"Pharmacokinetics of alemtuzumab used for in vivo and in vitro T\u2010cell depletion in allogeneic transplantations","volume":"102","author":"Morris EC","year":"2003","journal-title":"relevance for early adoptive immunotherapy and infectious complications"},{"issue":"12","key":"e_1_2_5_39_2","first-page":"1101","article-title":"In vivo Campath for the prevention of GvHD following allogeneic HSCT","volume":"34","author":"Russell NH","year":"2004","journal-title":"effects of dose, schedule and antibody type"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2009.00414.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2009.00414.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:30:58Z","timestamp":1696865458000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2009.00414.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1399-3062.2009.00414.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2009.00414.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}